Over-the-counter antibiotics compromising aminoglycoside activity Article Swipe
A. H. Robertson
,
Graça Coutinho
,
Efi Mantzourani
,
Barbara Szomolay
,
Thillagavathie Pillay
,
Adrian Shephard
,
Jean‐Yves Maillard
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1093/jac/dkae376
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1093/jac/dkae376
Introduction Antimicrobial resistance (AMR) is a global issue that needs addressing. While antibiotic stewardship has improved often by restricting antibiotic use, some antibiotics that are still sold legally over the counter (OTC), notably in sore throat medications. Recent findings suggest OTC antibiotics could trigger cross-resistance to antibiotics used in clinical treatments, whether systemic or topical. Here we investigated the impact of three antibiotics contained in OTC sore throat medicines on emerging AMR in vitro. Methods Bacterial pathogens were exposed to a bactericidal concentration of an aminoglycoside in the presence or absence of a during-use concentration of bacitracin, gramicidin or tyrothricin in a time–kill assay. Damage to the bacterial membrane was also investigated by measuring potassium leakage and membrane potential alteration post-OTC antibiotic exposure. Results Gramicidin (15 µg/mL) significantly decreased the bactericidal activity of amikacin, tobramycin or gentamicin in Acinetobacter baumannii. It also decreased gentamicin bactericidal activity in Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae, while tyrothricin decreased the aminoglycoside efficacy in E. cloacae and E. coli. Gramicidin significantly decreased bacterial membrane potential and caused significant potassium leakage. Conclusion Gramicidin and to some extent tyrothricin impacted aminoglycoside efficacy by affecting membrane potential, which is essential for aminoglycosides uptake. Thus, some OTC antibiotics can interfere with aminoglycoside activity, which could in turn affect treatment efficacy. Although the likelihood of OTC antibiotics and aminoglycosides being used at the same time might not be common, this research highlights one potential reason for OTC antibiotics’ usage to result in treatment failure and their contribution to AMR development.
Related Topics
Concepts
Aminoglycoside
Antibiotics
Tobramycin
Gentamicin
Microbiology
Polymyxin
Amikacin
Sisomicin
Bacitracin
Neomycin
Medicine
Pharmacology
Biology
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/jac/dkae376
- OA Status
- green
- References
- 30
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4403853078
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4403853078Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/jac/dkae376Digital Object Identifier
- Title
-
Over-the-counter antibiotics compromising aminoglycoside activityWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-10-29Full publication date if available
- Authors
-
A. H. Robertson, Graça Coutinho, Efi Mantzourani, Barbara Szomolay, Thillagavathie Pillay, Adrian Shephard, Jean‐Yves MaillardList of authors in order
- Landing page
-
https://doi.org/10.1093/jac/dkae376Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.ncbi.nlm.nih.gov/pmc/articles/11695918Direct OA link when available
- Concepts
-
Aminoglycoside, Antibiotics, Tobramycin, Gentamicin, Microbiology, Polymyxin, Amikacin, Sisomicin, Bacitracin, Neomycin, Medicine, Pharmacology, BiologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
30Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4403853078 |
|---|---|
| doi | https://doi.org/10.1093/jac/dkae376 |
| ids.doi | https://doi.org/10.1093/jac/dkae376 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39471310 |
| ids.openalex | https://openalex.org/W4403853078 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | Q000494 |
| mesh[0].descriptor_ui | D000900 |
| mesh[0].is_major_topic | True |
| mesh[0].qualifier_name | pharmacology |
| mesh[0].descriptor_name | Anti-Bacterial Agents |
| mesh[1].qualifier_ui | Q000494 |
| mesh[1].descriptor_ui | D004366 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | pharmacology |
| mesh[1].descriptor_name | Nonprescription Drugs |
| mesh[2].qualifier_ui | Q000494 |
| mesh[2].descriptor_ui | D000617 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | pharmacology |
| mesh[2].descriptor_name | Aminoglycosides |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008826 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Microbial Sensitivity Tests |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D006801 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Humans |
| mesh[5].qualifier_ui | Q000494 |
| mesh[5].descriptor_ui | D006096 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | pharmacology |
| mesh[5].descriptor_name | Gramicidin |
| mesh[6].qualifier_ui | Q000187 |
| mesh[6].descriptor_ui | D001419 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | drug effects |
| mesh[6].descriptor_name | Bacteria |
| mesh[7].qualifier_ui | Q000187 |
| mesh[7].descriptor_ui | D024881 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | drug effects |
| mesh[7].descriptor_name | Drug Resistance, Bacterial |
| mesh[8].qualifier_ui | Q000494 |
| mesh[8].descriptor_ui | D000900 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | pharmacology |
| mesh[8].descriptor_name | Anti-Bacterial Agents |
| mesh[9].qualifier_ui | Q000494 |
| mesh[9].descriptor_ui | D004366 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | pharmacology |
| mesh[9].descriptor_name | Nonprescription Drugs |
| mesh[10].qualifier_ui | Q000494 |
| mesh[10].descriptor_ui | D000617 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | pharmacology |
| mesh[10].descriptor_name | Aminoglycosides |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D008826 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Microbial Sensitivity Tests |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D006801 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Humans |
| mesh[13].qualifier_ui | Q000494 |
| mesh[13].descriptor_ui | D006096 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | pharmacology |
| mesh[13].descriptor_name | Gramicidin |
| mesh[14].qualifier_ui | Q000187 |
| mesh[14].descriptor_ui | D001419 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | drug effects |
| mesh[14].descriptor_name | Bacteria |
| mesh[15].qualifier_ui | Q000187 |
| mesh[15].descriptor_ui | D024881 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | drug effects |
| mesh[15].descriptor_name | Drug Resistance, Bacterial |
| mesh[16].qualifier_ui | Q000494 |
| mesh[16].descriptor_ui | D000900 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | pharmacology |
| mesh[16].descriptor_name | Anti-Bacterial Agents |
| mesh[17].qualifier_ui | Q000494 |
| mesh[17].descriptor_ui | D004366 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | pharmacology |
| mesh[17].descriptor_name | Nonprescription Drugs |
| mesh[18].qualifier_ui | Q000494 |
| mesh[18].descriptor_ui | D000617 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | pharmacology |
| mesh[18].descriptor_name | Aminoglycosides |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D008826 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Microbial Sensitivity Tests |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D006801 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Humans |
| mesh[21].qualifier_ui | Q000494 |
| mesh[21].descriptor_ui | D006096 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | pharmacology |
| mesh[21].descriptor_name | Gramicidin |
| mesh[22].qualifier_ui | Q000187 |
| mesh[22].descriptor_ui | D001419 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | drug effects |
| mesh[22].descriptor_name | Bacteria |
| mesh[23].qualifier_ui | Q000187 |
| mesh[23].descriptor_ui | D024881 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | drug effects |
| mesh[23].descriptor_name | Drug Resistance, Bacterial |
| mesh[24].qualifier_ui | Q000494 |
| mesh[24].descriptor_ui | D000900 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | pharmacology |
| mesh[24].descriptor_name | Anti-Bacterial Agents |
| mesh[25].qualifier_ui | Q000494 |
| mesh[25].descriptor_ui | D004366 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | pharmacology |
| mesh[25].descriptor_name | Nonprescription Drugs |
| mesh[26].qualifier_ui | Q000494 |
| mesh[26].descriptor_ui | D000617 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | pharmacology |
| mesh[26].descriptor_name | Aminoglycosides |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D008826 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Microbial Sensitivity Tests |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D006801 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Humans |
| mesh[29].qualifier_ui | Q000494 |
| mesh[29].descriptor_ui | D006096 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | pharmacology |
| mesh[29].descriptor_name | Gramicidin |
| mesh[30].qualifier_ui | Q000187 |
| mesh[30].descriptor_ui | D001419 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | drug effects |
| mesh[30].descriptor_name | Bacteria |
| mesh[31].qualifier_ui | Q000187 |
| mesh[31].descriptor_ui | D024881 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | drug effects |
| mesh[31].descriptor_name | Drug Resistance, Bacterial |
| type | article |
| title | Over-the-counter antibiotics compromising aminoglycoside activity |
| biblio.issue | 1 |
| biblio.volume | 80 |
| biblio.last_page | 94 |
| biblio.first_page | 87 |
| grants[0].funder | https://openalex.org/F4320320350 |
| grants[0].award_id | |
| grants[0].funder_display_name | Cardiff University |
| topics[0].id | https://openalex.org/T10897 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2402 |
| topics[0].subfield.display_name | Applied Microbiology and Biotechnology |
| topics[0].display_name | Antibiotic Use and Resistance |
| topics[1].id | https://openalex.org/T10147 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9995999932289124 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1313 |
| topics[1].subfield.display_name | Molecular Medicine |
| topics[1].display_name | Antibiotic Resistance in Bacteria |
| topics[2].id | https://openalex.org/T10195 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9991999864578247 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | Antimicrobial Resistance in Staphylococcus |
| funders[0].id | https://openalex.org/F4320320350 |
| funders[0].ror | https://ror.org/03kk7td41 |
| funders[0].display_name | Cardiff University |
| is_xpac | False |
| apc_list.value | 2627 |
| apc_list.currency | GBP |
| apc_list.value_usd | 3222 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777787772 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8152172565460205 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q45355603 |
| concepts[0].display_name | Aminoglycoside |
| concepts[1].id | https://openalex.org/C501593827 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8037705421447754 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[1].display_name | Antibiotics |
| concepts[2].id | https://openalex.org/C2778974779 |
| concepts[2].level | 4 |
| concepts[2].score | 0.6411830186843872 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1758380 |
| concepts[2].display_name | Tobramycin |
| concepts[3].id | https://openalex.org/C2775832221 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5820285081863403 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q422482 |
| concepts[3].display_name | Gentamicin |
| concepts[4].id | https://openalex.org/C89423630 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5754698514938354 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[4].display_name | Microbiology |
| concepts[5].id | https://openalex.org/C2780675486 |
| concepts[5].level | 3 |
| concepts[5].score | 0.48180264234542847 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q423765 |
| concepts[5].display_name | Polymyxin |
| concepts[6].id | https://openalex.org/C2777427914 |
| concepts[6].level | 3 |
| concepts[6].score | 0.4511508047580719 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q408529 |
| concepts[6].display_name | Amikacin |
| concepts[7].id | https://openalex.org/C2780346086 |
| concepts[7].level | 5 |
| concepts[7].score | 0.4403139054775238 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q3962119 |
| concepts[7].display_name | Sisomicin |
| concepts[8].id | https://openalex.org/C2779860364 |
| concepts[8].level | 3 |
| concepts[8].score | 0.43469470739364624 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q61954719 |
| concepts[8].display_name | Bacitracin |
| concepts[9].id | https://openalex.org/C2779841869 |
| concepts[9].level | 3 |
| concepts[9].score | 0.4274415373802185 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q423098 |
| concepts[9].display_name | Neomycin |
| concepts[10].id | https://openalex.org/C71924100 |
| concepts[10].level | 0 |
| concepts[10].score | 0.3757936954498291 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[10].display_name | Medicine |
| concepts[11].id | https://openalex.org/C98274493 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3656858205795288 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[11].display_name | Pharmacology |
| concepts[12].id | https://openalex.org/C86803240 |
| concepts[12].level | 0 |
| concepts[12].score | 0.25283366441726685 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[12].display_name | Biology |
| keywords[0].id | https://openalex.org/keywords/aminoglycoside |
| keywords[0].score | 0.8152172565460205 |
| keywords[0].display_name | Aminoglycoside |
| keywords[1].id | https://openalex.org/keywords/antibiotics |
| keywords[1].score | 0.8037705421447754 |
| keywords[1].display_name | Antibiotics |
| keywords[2].id | https://openalex.org/keywords/tobramycin |
| keywords[2].score | 0.6411830186843872 |
| keywords[2].display_name | Tobramycin |
| keywords[3].id | https://openalex.org/keywords/gentamicin |
| keywords[3].score | 0.5820285081863403 |
| keywords[3].display_name | Gentamicin |
| keywords[4].id | https://openalex.org/keywords/microbiology |
| keywords[4].score | 0.5754698514938354 |
| keywords[4].display_name | Microbiology |
| keywords[5].id | https://openalex.org/keywords/polymyxin |
| keywords[5].score | 0.48180264234542847 |
| keywords[5].display_name | Polymyxin |
| keywords[6].id | https://openalex.org/keywords/amikacin |
| keywords[6].score | 0.4511508047580719 |
| keywords[6].display_name | Amikacin |
| keywords[7].id | https://openalex.org/keywords/sisomicin |
| keywords[7].score | 0.4403139054775238 |
| keywords[7].display_name | Sisomicin |
| keywords[8].id | https://openalex.org/keywords/bacitracin |
| keywords[8].score | 0.43469470739364624 |
| keywords[8].display_name | Bacitracin |
| keywords[9].id | https://openalex.org/keywords/neomycin |
| keywords[9].score | 0.4274415373802185 |
| keywords[9].display_name | Neomycin |
| keywords[10].id | https://openalex.org/keywords/medicine |
| keywords[10].score | 0.3757936954498291 |
| keywords[10].display_name | Medicine |
| keywords[11].id | https://openalex.org/keywords/pharmacology |
| keywords[11].score | 0.3656858205795288 |
| keywords[11].display_name | Pharmacology |
| keywords[12].id | https://openalex.org/keywords/biology |
| keywords[12].score | 0.25283366441726685 |
| keywords[12].display_name | Biology |
| language | en |
| locations[0].id | doi:10.1093/jac/dkae376 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S124275759 |
| locations[0].source.issn | 0305-7453, 1460-2091 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0305-7453 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Journal of Antimicrobial Chemotherapy |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Journal of Antimicrobial Chemotherapy |
| locations[0].landing_page_url | https://doi.org/10.1093/jac/dkae376 |
| locations[1].id | pmid:39471310 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | The Journal of antimicrobial chemotherapy |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39471310 |
| locations[2].id | pmh:oai:https://orca.cardiff.ac.uk:173727 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306400871 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Spectrum Research Repository (Concordia University) |
| locations[2].source.host_organization | https://openalex.org/I60158472 |
| locations[2].source.host_organization_name | Concordia University |
| locations[2].source.host_organization_lineage | https://openalex.org/I60158472 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | acceptedVersion |
| locations[2].raw_type | PeerReviewed |
| locations[2].license_id | |
| locations[2].is_accepted | True |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:11695918 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | J Antimicrob Chemother |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11695918 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5049922387 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5345-7846 |
| authorships[0].author.display_name | A. H. Robertson |
| authorships[0].countries | GB |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I79510175 |
| authorships[0].affiliations[0].raw_affiliation_string | School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , |
| authorships[0].institutions[0].id | https://openalex.org/I79510175 |
| authorships[0].institutions[0].ror | https://ror.org/03kk7td41 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I79510175 |
| authorships[0].institutions[0].country_code | GB |
| authorships[0].institutions[0].display_name | Cardiff University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | A Robertson |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , |
| authorships[1].author.id | https://openalex.org/A5021236810 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9580-5949 |
| authorships[1].author.display_name | Graça Coutinho |
| authorships[1].countries | GB |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210115825 |
| authorships[1].affiliations[0].raw_affiliation_string | Medical Marketing, Reckitt Benckiser , Slough , |
| authorships[1].institutions[0].id | https://openalex.org/I4210115825 |
| authorships[1].institutions[0].ror | https://ror.org/01g87hr29 |
| authorships[1].institutions[0].type | company |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210115825 |
| authorships[1].institutions[0].country_code | GB |
| authorships[1].institutions[0].display_name | Reckitt Benckiser (United Kingdom) |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | G Coutinho |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Medical Marketing, Reckitt Benckiser , Slough , |
| authorships[2].author.id | https://openalex.org/A5065166396 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6313-1409 |
| authorships[2].author.display_name | Efi Mantzourani |
| authorships[2].countries | GB |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I79510175 |
| authorships[2].affiliations[0].raw_affiliation_string | School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , |
| authorships[2].institutions[0].id | https://openalex.org/I79510175 |
| authorships[2].institutions[0].ror | https://ror.org/03kk7td41 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I79510175 |
| authorships[2].institutions[0].country_code | GB |
| authorships[2].institutions[0].display_name | Cardiff University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | E Mantzourani |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , |
| authorships[3].author.id | https://openalex.org/A5039685491 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-5375-5533 |
| authorships[3].author.display_name | Barbara Szomolay |
| authorships[3].countries | GB |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I79510175 |
| authorships[3].affiliations[0].raw_affiliation_string | School of Medicine, Cardiff University , Cardiff , |
| authorships[3].institutions[0].id | https://openalex.org/I79510175 |
| authorships[3].institutions[0].ror | https://ror.org/03kk7td41 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I79510175 |
| authorships[3].institutions[0].country_code | GB |
| authorships[3].institutions[0].display_name | Cardiff University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | B Szomolay |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | School of Medicine, Cardiff University , Cardiff , |
| authorships[4].author.id | https://openalex.org/A5088197439 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-4159-3282 |
| authorships[4].author.display_name | Thillagavathie Pillay |
| authorships[4].countries | GB |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210115825 |
| authorships[4].affiliations[0].raw_affiliation_string | Medical Marketing, Reckitt Benckiser , Slough , |
| authorships[4].institutions[0].id | https://openalex.org/I4210115825 |
| authorships[4].institutions[0].ror | https://ror.org/01g87hr29 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210115825 |
| authorships[4].institutions[0].country_code | GB |
| authorships[4].institutions[0].display_name | Reckitt Benckiser (United Kingdom) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | T Pillay |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Medical Marketing, Reckitt Benckiser , Slough , |
| authorships[5].author.id | https://openalex.org/A5085088033 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-4020-1486 |
| authorships[5].author.display_name | Adrian Shephard |
| authorships[5].countries | GB |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210115825 |
| authorships[5].affiliations[0].raw_affiliation_string | Medical Marketing, Reckitt Benckiser , Slough , |
| authorships[5].institutions[0].id | https://openalex.org/I4210115825 |
| authorships[5].institutions[0].ror | https://ror.org/01g87hr29 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210115825 |
| authorships[5].institutions[0].country_code | GB |
| authorships[5].institutions[0].display_name | Reckitt Benckiser (United Kingdom) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | A Shephard |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Medical Marketing, Reckitt Benckiser , Slough , |
| authorships[6].author.id | https://openalex.org/A5054367285 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-8617-9288 |
| authorships[6].author.display_name | Jean‐Yves Maillard |
| authorships[6].countries | GB |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I79510175 |
| authorships[6].affiliations[0].raw_affiliation_string | School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , |
| authorships[6].institutions[0].id | https://openalex.org/I79510175 |
| authorships[6].institutions[0].ror | https://ror.org/03kk7td41 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I79510175 |
| authorships[6].institutions[0].country_code | GB |
| authorships[6].institutions[0].display_name | Cardiff University |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | J Y Maillard |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff , |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11695918 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Over-the-counter antibiotics compromising aminoglycoside activity |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10897 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2402 |
| primary_topic.subfield.display_name | Applied Microbiology and Biotechnology |
| primary_topic.display_name | Antibiotic Use and Resistance |
| related_works | https://openalex.org/W2082009934, https://openalex.org/W2410148848, https://openalex.org/W2315757041, https://openalex.org/W3126959613, https://openalex.org/W2076817377, https://openalex.org/W3024108938, https://openalex.org/W2410693635, https://openalex.org/W1997199630, https://openalex.org/W3185719395, https://openalex.org/W4252292695 |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:11695918 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | other-oa |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | https://openalex.org/licenses/other-oa |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | J Antimicrob Chemother |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11695918 |
| primary_location.id | doi:10.1093/jac/dkae376 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S124275759 |
| primary_location.source.issn | 0305-7453, 1460-2091 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0305-7453 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Journal of Antimicrobial Chemotherapy |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Journal of Antimicrobial Chemotherapy |
| primary_location.landing_page_url | https://doi.org/10.1093/jac/dkae376 |
| publication_date | 2024-10-29 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W1992000185, https://openalex.org/W2906150927, https://openalex.org/W2140353364, https://openalex.org/W4399302728, https://openalex.org/W2968757452, https://openalex.org/W4307092419, https://openalex.org/W2408867680, https://openalex.org/W2474629458, https://openalex.org/W2513811384, https://openalex.org/W6725798680, https://openalex.org/W2057120022, https://openalex.org/W1976111797, https://openalex.org/W2131709544, https://openalex.org/W82471831, https://openalex.org/W6714040044, https://openalex.org/W3021391994, https://openalex.org/W3210022800, https://openalex.org/W2934656438, https://openalex.org/W6843906961, https://openalex.org/W6603342938, https://openalex.org/W2416290591, https://openalex.org/W1901312711, https://openalex.org/W3146941526, https://openalex.org/W2131545005, https://openalex.org/W2488529222, https://openalex.org/W2013539269, https://openalex.org/W2218682325, https://openalex.org/W2900649343, https://openalex.org/W1787488026, https://openalex.org/W2126055537 |
| referenced_works_count | 30 |
| abstract_inverted_index.a | 6, 81, 93, 102 |
| abstract_inverted_index.E. | 162, 165 |
| abstract_inverted_index.It | 141 |
| abstract_inverted_index.an | 85 |
| abstract_inverted_index.at | 224 |
| abstract_inverted_index.be | 230 |
| abstract_inverted_index.by | 18, 113, 188 |
| abstract_inverted_index.in | 34, 49, 65, 73, 87, 101, 138, 147, 161, 209, 244 |
| abstract_inverted_index.is | 5, 193 |
| abstract_inverted_index.of | 61, 84, 92, 96, 133, 217 |
| abstract_inverted_index.on | 70 |
| abstract_inverted_index.or | 54, 90, 99, 136 |
| abstract_inverted_index.to | 46, 80, 106, 181, 242, 250 |
| abstract_inverted_index.we | 57 |
| abstract_inverted_index.(15 | 126 |
| abstract_inverted_index.AMR | 72, 251 |
| abstract_inverted_index.OTC | 41, 66, 200, 218, 239 |
| abstract_inverted_index.and | 117, 152, 164, 173, 180, 220, 247 |
| abstract_inverted_index.are | 25 |
| abstract_inverted_index.can | 202 |
| abstract_inverted_index.for | 195, 238 |
| abstract_inverted_index.has | 15 |
| abstract_inverted_index.not | 229 |
| abstract_inverted_index.one | 235 |
| abstract_inverted_index.the | 30, 59, 88, 107, 130, 158, 215, 225 |
| abstract_inverted_index.was | 110 |
| abstract_inverted_index.Here | 56 |
| abstract_inverted_index.also | 111, 142 |
| abstract_inverted_index.coli | 151 |
| abstract_inverted_index.over | 29 |
| abstract_inverted_index.same | 226 |
| abstract_inverted_index.sold | 27 |
| abstract_inverted_index.some | 22, 182, 199 |
| abstract_inverted_index.sore | 35, 67 |
| abstract_inverted_index.that | 9, 24 |
| abstract_inverted_index.this | 232 |
| abstract_inverted_index.time | 227 |
| abstract_inverted_index.turn | 210 |
| abstract_inverted_index.use, | 21 |
| abstract_inverted_index.used | 48, 223 |
| abstract_inverted_index.were | 78 |
| abstract_inverted_index.with | 204 |
| abstract_inverted_index.(AMR) | 4 |
| abstract_inverted_index.Thus, | 198 |
| abstract_inverted_index.While | 12 |
| abstract_inverted_index.being | 222 |
| abstract_inverted_index.coli. | 166 |
| abstract_inverted_index.could | 43, 208 |
| abstract_inverted_index.issue | 8 |
| abstract_inverted_index.might | 228 |
| abstract_inverted_index.needs | 10 |
| abstract_inverted_index.often | 17 |
| abstract_inverted_index.still | 26 |
| abstract_inverted_index.their | 248 |
| abstract_inverted_index.three | 62 |
| abstract_inverted_index.usage | 241 |
| abstract_inverted_index.which | 192, 207 |
| abstract_inverted_index.while | 155 |
| abstract_inverted_index.(OTC), | 32 |
| abstract_inverted_index.Damage | 105 |
| abstract_inverted_index.Recent | 38 |
| abstract_inverted_index.affect | 211 |
| abstract_inverted_index.assay. | 104 |
| abstract_inverted_index.caused | 174 |
| abstract_inverted_index.extent | 183 |
| abstract_inverted_index.global | 7 |
| abstract_inverted_index.impact | 60 |
| abstract_inverted_index.reason | 237 |
| abstract_inverted_index.result | 243 |
| abstract_inverted_index.throat | 36, 68 |
| abstract_inverted_index.vitro. | 74 |
| abstract_inverted_index.Methods | 75 |
| abstract_inverted_index.Results | 124 |
| abstract_inverted_index.absence | 91 |
| abstract_inverted_index.cloacae | 163 |
| abstract_inverted_index.common, | 231 |
| abstract_inverted_index.counter | 31 |
| abstract_inverted_index.exposed | 79 |
| abstract_inverted_index.failure | 246 |
| abstract_inverted_index.leakage | 116 |
| abstract_inverted_index.legally | 28 |
| abstract_inverted_index.notably | 33 |
| abstract_inverted_index.suggest | 40 |
| abstract_inverted_index.trigger | 44 |
| abstract_inverted_index.uptake. | 197 |
| abstract_inverted_index.whether | 52 |
| abstract_inverted_index.µg/mL) | 127 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Although | 214 |
| abstract_inverted_index.activity | 132, 146 |
| abstract_inverted_index.clinical | 50 |
| abstract_inverted_index.cloacae, | 149 |
| abstract_inverted_index.efficacy | 160, 187 |
| abstract_inverted_index.emerging | 71 |
| abstract_inverted_index.findings | 39 |
| abstract_inverted_index.impacted | 185 |
| abstract_inverted_index.improved | 16 |
| abstract_inverted_index.leakage. | 177 |
| abstract_inverted_index.membrane | 109, 118, 171, 190 |
| abstract_inverted_index.post-OTC | 121 |
| abstract_inverted_index.presence | 89 |
| abstract_inverted_index.research | 233 |
| abstract_inverted_index.systemic | 53 |
| abstract_inverted_index.topical. | 55 |
| abstract_inverted_index.Bacterial | 76 |
| abstract_inverted_index.activity, | 206 |
| abstract_inverted_index.affecting | 189 |
| abstract_inverted_index.amikacin, | 134 |
| abstract_inverted_index.bacterial | 108, 170 |
| abstract_inverted_index.contained | 64 |
| abstract_inverted_index.decreased | 129, 143, 157, 169 |
| abstract_inverted_index.efficacy. | 213 |
| abstract_inverted_index.essential | 194 |
| abstract_inverted_index.exposure. | 123 |
| abstract_inverted_index.interfere | 203 |
| abstract_inverted_index.measuring | 114 |
| abstract_inverted_index.medicines | 69 |
| abstract_inverted_index.pathogens | 77 |
| abstract_inverted_index.potassium | 115, 176 |
| abstract_inverted_index.potential | 119, 172, 236 |
| abstract_inverted_index.treatment | 212, 245 |
| abstract_inverted_index.Conclusion | 178 |
| abstract_inverted_index.Gramicidin | 125, 167, 179 |
| abstract_inverted_index.Klebsiella | 153 |
| abstract_inverted_index.alteration | 120 |
| abstract_inverted_index.antibiotic | 13, 20, 122 |
| abstract_inverted_index.baumannii. | 140 |
| abstract_inverted_index.during-use | 94 |
| abstract_inverted_index.gentamicin | 137, 144 |
| abstract_inverted_index.gramicidin | 98 |
| abstract_inverted_index.highlights | 234 |
| abstract_inverted_index.likelihood | 216 |
| abstract_inverted_index.potential, | 191 |
| abstract_inverted_index.resistance | 3 |
| abstract_inverted_index.tobramycin | 135 |
| abstract_inverted_index.Escherichia | 150 |
| abstract_inverted_index.addressing. | 11 |
| abstract_inverted_index.antibiotics | 23, 42, 47, 63, 201, 219 |
| abstract_inverted_index.bacitracin, | 97 |
| abstract_inverted_index.pneumoniae, | 154 |
| abstract_inverted_index.restricting | 19 |
| abstract_inverted_index.significant | 175 |
| abstract_inverted_index.stewardship | 14 |
| abstract_inverted_index.time–kill | 103 |
| abstract_inverted_index.treatments, | 51 |
| abstract_inverted_index.tyrothricin | 100, 156, 184 |
| abstract_inverted_index.Enterobacter | 148 |
| abstract_inverted_index.Introduction | 1 |
| abstract_inverted_index.bactericidal | 82, 131, 145 |
| abstract_inverted_index.contribution | 249 |
| abstract_inverted_index.development. | 252 |
| abstract_inverted_index.investigated | 58, 112 |
| abstract_inverted_index.medications. | 37 |
| abstract_inverted_index.Acinetobacter | 139 |
| abstract_inverted_index.Antimicrobial | 2 |
| abstract_inverted_index.concentration | 83, 95 |
| abstract_inverted_index.significantly | 128, 168 |
| abstract_inverted_index.aminoglycoside | 86, 159, 186, 205 |
| abstract_inverted_index.antibiotics’ | 240 |
| abstract_inverted_index.aminoglycosides | 196, 221 |
| abstract_inverted_index.cross-resistance | 45 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 7 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.75 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.25713087 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |